9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Isolated Thoracic Perfusion (ITP-F) for MPM

ConditionMesotheliomaEstimated Enrollment: 23Age Group: 18 Years to 80 Years   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Case Control|Time Perspective: ProspectiveStudy ID Numbers: 0001Study First Received: May 26, 2015Last Updated: June 9, 2015Estimated Primary Completion Date: January 2015Primary Outcome Measures:Survival|ToxicitySponsors and Collaborators:Medias Klinikum for Surgical OncologyResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02467426...

Continue reading

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

ConditionMesotheliomaEstimated Enrollment: 448Age Group: 18 Years to 75 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: IFCT-GFPC-0701Study First Received: March 29, 2008Last Updated: September 1, 2016Estimated Primary Completion Date: January 2015Primary Outcome Measures:% of patients with controled disease (responder and stable patients) at 6 months|Overall Survival|Number of participants with treatment-related adverse events as assessed by CTCAE v3.0Sponsors and Collaborators:Intergroupe Francophone de Cancerologie Thoracique|University Hospital, Caen|Groupe Francais De Pneumo-CancerologieResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00651456...

Continue reading

Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 45Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: ELCWP-01062Study First Received: March 5, 2008Last Updated: February 11, 2015Estimated Primary Completion Date: March 2009Primary Outcome Measures:Response rate|Survival|ToxicitySponsors and Collaborators:European Lung Cancer Working PartyResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00634205...

Continue reading

Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma

ConditionMalignant Mesothelioma|Metastatic CancerEstimated Enrollment: 196Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: P00804|PAPWORTH-MESOVATS|PAPWORTH-P00804|EU-20901|ISRCTN34321019Study First Received: January 13, 2009Last Updated: June 27, 2013Estimated Primary Completion Date: February 2013Primary Outcome Measures:Survival at 1 year after treatment|Control of pleural effusion|Complications, including need for more surgery, persistent air leak requiring pleural intubation for > 10 days, and hospital stay for > 12 days|Symptoms and quality of life as assessed by the EuroQol questionnaire|Length of hospital stay|Exercise tolerance|Cost to the health service, in terms of resources used for...

Continue reading

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

ConditionPart A and B: Advanced Solid Malignancies|Part C: Malignant MesotheliomaEstimated Enrollment: 73Age Group: 20 Years to 130 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Masking: No masking|Primary Purpose: OtherStudy ID Numbers: D4880C00010Study First Received: May 14, 2014Last Updated: April 12, 2017Estimated Primary Completion Date: January 27, 2017Primary Outcome Measures:Adverse eventSponsors and Collaborators:AstraZenecaResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02141347...

Continue reading

Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma

ConditionLung Cancer|Malignant MesotheliomaEstimated Enrollment: 20Age Group: 20 Years to 70 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Primary Purpose: TreatmentStudy ID Numbers: CDR0000067177|RPCI-DS-96-25Study First Received: November 1, 1999Last Updated: March 3, 2011Estimated Primary Completion Date: June 1998Primary Outcome Measures:Sponsors and Collaborators:Roswell Park Cancer InstituteResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00003974...

Continue reading

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

ConditionMesotheliomaEstimated Enrollment: 8Age Group: 19 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: F090917002 (UAB 0901)|UAB 0901Study First Received: September 15, 2010Last Updated: May 20, 2016Estimated Primary Completion Date: April 2015Primary Outcome Measures:Evaluation of the tumor response rate following zoledronic acid|Evaluation of the duration of tumor responseSponsors and Collaborators:University of Alabama at Birmingham|Novartis PharmaceuticalsResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01204203...

Continue reading

Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 30Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Primary Purpose: TreatmentStudy ID Numbers: CDR0000066141|P30CA016087|NYU-9850|MDA-FDR001234|MDA-ID-95209|NCI-G99-1575Study First Received: December 10, 1999Last Updated: March 25, 2011Estimated Primary Completion Date: May 2001Primary Outcome Measures:Sponsors and Collaborators:New York University School of Medicine|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00004033...

Continue reading

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 77Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: ONC-2006-003|EUDRACT 2006-004429-27Study First Received: December 4, 2006Last Updated: August 31, 2011Estimated Primary Completion Date: November 2010Primary Outcome Measures:Time to progression (TTP) from first day of treatment until first observation of disease progression or death due to any cause or the last date the patient was known to be progression free or alive.|Response rate (RR) assessed according to modified RECIST criteria for Malignant Pleural Mesothelioma.|Overall survival (OS) computed as the time between the...

Continue reading

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

ConditionAdvanced Malignant Mesothelioma|Recurrent Malignant MesotheliomaEstimated Enrollment: 39Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NCI-2009-00693|CDR0000652058|NCIC-183Study First Received: October 25, 2006Last Updated: May 5, 2014Estimated Primary Completion Date: January 2012Primary Outcome Measures:Objective Response (Partial and Complete) Per RECISTSponsors and Collaborators:National Cancer Institute (NCI)Result Received: October 21, 2013Website Link: https://ClinicalTrials.gov/show/NCT00392444...

Continue reading